These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34625019)

  • 1. Inflammatory complications of CGRP monoclonal antibodies: a case series.
    Ray JC; Allen P; Bacsi A; Bosco JJ; Chen L; Eller M; Kua H; Lim LL; Matharu MS; Monif M; Ruttledge M; Stark RJ; Hutton EJ
    J Headache Pain; 2021 Oct; 22(1):121. PubMed ID: 34625019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST; Wu JW
    Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
    Bigal ME; Walter S
    CNS Drugs; 2014 May; 28(5):389-99. PubMed ID: 24638916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.
    Breen ID; Brumfiel CM; Patel MH; Butterfield RJ; VanderPluym JH; Griffing L; Pittelkow MR; Mangold AR
    JAMA Netw Open; 2021 Apr; 4(4):e217934. PubMed ID: 33871613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody.
    Melo-Carrillo A; Noseda R; Nir RR; Schain AJ; Stratton J; Strassman AM; Burstein R
    J Neurosci; 2017 Jul; 37(30):7149-7163. PubMed ID: 28642283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K; Reynolds J; Sands KA; Shiue HJ
    Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
    [No Abstract]   [Full Text] [Related]  

  • 12. Calcitonin gene-related peptide and migraine.
    Karsan N; Goadsby PJ
    Curr Opin Neurol; 2015 Jun; 28(3):250-4. PubMed ID: 25887765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of calcitonin gene-related peptide action as a new strategy for migraine treatment.
    Kuzawińska O; Lis K; Cessak G; Mirowska-Guzel D; Bałkowiec-Iskra E
    Neurol Neurochir Pol; 2016; 50(6):463-467. PubMed ID: 27553188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series.
    Briceño-Casado MDP; Gil-Sierra MD; De-La-Calle-Riaguas B
    Eur J Hosp Pharm; 2023 Jul; 30(4):e19. PubMed ID: 34521726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fremanezumab for the preventive treatment of migraine in adults.
    Lionetto L; Curto M; Cisale GY; Capi M; Cipolla F; Guglielmetti M; Martelletti P
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):741-748. PubMed ID: 31220963
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
    Kang SA; Govindarajan R
    Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System.
    Chong CM; Zhong Z; Vong CT; Wang S; Lu JJ; Zhong HJ; Su H; Wang Y
    Curr Neuropharmacol; 2021; 19(7):1090-1100. PubMed ID: 33121411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.
    Melo-Carrillo A; Strassman AM; Nir RR; Schain AJ; Noseda R; Stratton J; Burstein R
    J Neurosci; 2017 Nov; 37(44):10587-10596. PubMed ID: 28972120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?
    Al-Hassany L; Boucherie DM; Couturier EGM; MaassenVanDenBrink A
    Cephalalgia; 2024 May; 44(5):3331024241248837. PubMed ID: 38796855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.